The treatment of patients with psoriasis has evolved over the decade, and currently biologics have become the first-line treatments in patients who are candidates for systemic treatment due to their favorable efficacy and safety. Improvement in 75% of Psoriasis Area Severity Index (PASI 75) had been the primary treatment target of psoriasis; however, the bar has been raised to PASI 90 since the advent of secukinumab, [1] an interleukin-17 (IL-17) blocker, which has been approved for more than 3 years for psoriasis treatment. Secukinumab has also been reported to be effective in patients who had failed on multiple prior biologics, [2] [3] [4] and sustained efficacy was reported up to 5 years. [5] However, primary or secondary failure of secukinumab is not uncommon, [6] and the treatment choice in these inadequate responders remains poorly studied. Here, we aim to report our experience in treating patients who had failed on prior secukinumab treatment.
MEthods
This is a retrospective observational study. We review the treatment efficacy of all patients who used secukinumab as monotherapy for moderate-to-severe plaque psoriasis (defined as at least baseline PASI = 12 and body surface area = 10%) in our clinic. All patients who received secukinumab alone for more than 6 months but had inadequate response were included, defined as failure to reach or maintain PASI 75 response after week 16 compared to baseline. The primary failure is defined as failure to reach PASI 75 after applying the biologics, whereas the secondary failure is defined as failure to maintain PASI 75 after treatment. Subsequent treatment response was recorded for those who were treated with systemic modalities for at least 16 weeks. PASI response was assessed by the same physician when the patients came back to our clinic. Due to variable time to optimal responses of the systemic treatment, we recorded PASI improvement between weeks 12 and 20 and also at the end of observation period.
rEsults
We included 16 male patients in the study, among whom 7 patients never reached PASI 75, and the others had secondary loss of efficacy. Most of them (6/9) had secondary failure to secukinumab in 1 year. Seven of the 16 patients maintained PASI 50 at the end of the treatment, but they were not satisfied with the treatment effect. All of them got deteriorated after cessation of the biologics. The patient demographics and characteristics are listed in Table 1 .
All of the patients received regular follow-up at our outpatient clinic after secukinumab failure. Traditional systemic treatment (i.e., methotrexate, acitretin, cyclosporine, or phototherapy), etanercept, adalimumab, secukinumab weekly reloading, or ustekinumab was administered. The therapeutic responses are listed in Table 2 . Only six patients reached PASI 75 at week 16, including three with adalimumab, one with traditional systemic treatment, one with secukinumab, and one with ustekinumab [ Figure 1a ]. At the end of follow-up, PASI 75 response was maintained in only four patients. Two of them used adalimumab, one used methotrexate plus acitretin, and the other used secukinumab [ Table 2 ].
We also divided the nonresponders into primary and secondary failures. For those with primary failure to secukinumab [ Figure 1b ], one patient (case 9) with adalimumab and the other one (case 13) with methotrexate plus acitretin revealed optimal improvement at follow-up after 1 year. For secondary nonresponders to secukinumab, more patients on adalimumab demonstrated PASI 75 response than those on other biologics: three of four patients with adalimumab at week 16, one of two with secukinumab, and one of two with ustekinumab [ Figure 1c ]. None of the patients who used nonbiologic systemic treatment reached PASI 75 in this group.
disCussion
The treatment of moderate-to-severe psoriasis had evolved significantly since the introduction of biologics. Newer biologics have been approved as the first-line treatment for [7] etanercept, [8] or ustekinumab, [9] after adalimumab/infliximab, and secukinumab after ustekinumab exist. [4] Moreover for secukinumab failure, there is one recent article which showed ixekizumab, a novel IL-17 inhibitor, to be effective. [10] Secukinumab is the first approved IL-17 inhibitor for psoriasis treatment. In the FIXTURE study, PASI 75 was achieved by 77.1% with 300 mg of secukinumab and 67.0% with 150 mg of secukinumab at week 12. [11] In CLEAR study, the peak response occurred at week 16 when PASI 90 response was achieved by 79.0% with 300 mg secukinumab and 57.6% with ustekinumab. [1] Secukinumab showed sustained therapeutic effects in pivotal clinical studies; [5] however, the therapeutic effect seemed to decrease gradually in the real world. [12, 13] The treatment efficacy for those who failed prior secukinumab has not been well studied. In one study, ixekizumab was reported to be highly effective in patients who failed on primary secukinumab. At least PASI 75 response or Physician Global Assessment 0/1 was achieved in 4/4 of primary nonresponders and in 8/9 of secondary nonresponders after the use of ixekizumab. [10] However, the exact baseline and posttreatment PASI were not provided. In the other study, over a 2-year time horizon, the treatment sequence of secukinumab-adalimumab-ustekinumab offered the lowest cost per PASI 90 responder. [14] At the time of our study, because ixekizumab was only recently available, other treatment modalities were used in our patients who failed secukinumab. The choice of treatment was determined as follows: 1. For patients who have not failed prior systemic therapy or do not fulfill the current reimbursement criteria for biologics, conventional treatment will be given first (cases 10, 11, 13, and 15) 2. The biologics which the patients had failed previously will be excluded (cases 1, 2, 4, 6, 8, and 9) 3. Patients with secondary failure to secukinumab will receive reloading of secukinumab if the patients were willing to self-pay for the additional secukinumab (patients 5 and 12) 4. If the patient had used all the currently available biologics, the biologics which produced the best response (at least PASI 50 response) would be re-applied (cases 3, 7, 14, and 16).
Among the treatments, adalimumab seems to demonstrate better response compared to the other biologics or secukinumab reloading. In addition, traditional therapy has resulted in at least PASI 50 response in 75% (3/4) of the patients, including PASI 75 in one patient at the last administration [ Table 3 ]. Patients who had secondary failure seem to respond to the switched treatment better than those with primary failure. Compared to switching to ixekizumab, [10] the treatment response in our study is less impressive. However, because of difference in inclusion criteria and prior treatment, it is not known if ixekizumab will be a preferred choice compared to other biologics for those who failed on prior secukinumab since both ixekizumab and secukinumab share similar mode of action as IL-17 blockers. 
ConClusion
In this study, we reported our treatment experience in patients with refractory psoriasis to secukinumab. Adalimumab seems to work slightly better than ustekinumab, possibly due to different modes of action. However, traditional systemic medication and re-loading of secukinumab can also provide some benefits. However, both our and prior studies were limited by small case number, heterogeneous prior treatments, and relative short follow-up period after switching into new treatment. To provide stronger evidence-based recommendations, controlled studies to re-randomize more patients who fail on secukinumab into different treatment groups of biologics, such as adalimumab, ustekinumab, guselkumab, or ixekizumab, will be needed. 
